Alternate-Day Buprenorphine Administration. Phase IV - 5
Phase 2
Completed
- Conditions
- Opioid-Related Disorders
- Registration Number
- NCT00000223
- Lead Sponsor
- National Institute on Drug Abuse (NIDA)
- Brief Summary
The purpose of this study is to determine if three times a subject's daily maintenance dose will hold for 72 hours without changes in agonist and antagonist effects.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Primary Outcome Measures
Name Time Method Drug use Opioid withdrawal Opioid agonist effects Dose identification Pupil diameter
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Treatment Research Center
🇺🇸Burlington, Vermont, United States